Showing results (181-190 of 346) with videos related to

Sort By:
Pageof 35
Antimicrobial Agents and Chemotherapy|May 8, 2013
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteersDavid Tenero, Gary Bowers, Keith A Rodvold, et al.
Medicine|March 9, 2017
Recurrent Clostridium difficile infection among Medicare patients in nursing homes: A population-based cohort studyMarya D Zilberberg, Andrew F Shorr, William M Jesdale, et al.
Surgical Infections|December 11, 2012
Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapyMarya Zilberberg, Scott T Micek, Marin H Kollef, et al.
BMC Infectious Diseases|April 19, 2017
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsisMarya D Zilberberg, Brian H Nathanson, Kate Sulham, et al.
Critical Care (London, England)|July 16, 2016
Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsisMarya D Zilberberg, Brian H Nathanson, Kate Sulham, et al.
Critical Care Medicine|July 25, 2012
Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patientsSteven C Reynolds, Andrew F Shorr, John Muscedere, et al.
Chest|April 30, 2011
Validation of a novel risk score for severity of illness in acute exacerbations of COPDAndrew F Shorr, Xiaowu Sun, Richard S Johannes, et al.
Antibiotics (Basel, Switzerland)|March 28, 2025
Unfavorable Outcomes and Their Risk Factors in Hospitalized Patients with Staphylococcus aureus Bacteremia in the US: A Multicenter Retrospective Cohort Study, 2020-2022Marya D Zilberberg, Brian H Nathanson, Rolf Wagenaar, et al.
Respiratory Medicine|January 24, 2021
Pneumococal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistanceAndrew F Shorr, James Simmons, Nicolas Hampton, et al.
Diagnostic Microbiology and Infectious Disease|January 30, 2013
Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trialsAndrew F Shorr, Marin Kollef, Paul B Eckburg, et al.
Pageof 35